AN2 Therapeutics reports Q3 2024 net loss $12.7M, positive Phase 2 epetraborole PRO data in TR-MAC

AN2 Therapeutics, Inc.

2024-Q3 EPS reported -$1.47

Net loss $12.7M in Q3 2024 vs $16.7M in Q3 2023; cash $93.4M, expected to fund operations through 2027.
Phase 2 portion of EBO-301: epetraborole achieved nominally significant improvements in QOL-B (p=0.0365) and MACrO2 (p=0.0433) vs placebo.
Company plans to meet FDA in H1 2025 to discuss reinitiating Phase 3 TR-MAC study and top-line Phase 3 data in mid-2025.
Achieved 50% reduction in expenditures through strategic realignment; R&D expenses decreased to $8.3M from $14.4M.
Advancing boron chemistry pipeline: Chagas Phase 1 mid-2025, melioidosis Phase 2 enrollment H2 2025, and Gates Foundation grant.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.